Evidence map›Paper›PMID 38203539›Full record

ReviewInternational journal of molecular sciences2023

Withaferin A and Celastrol Overwhelm Proteostasis.

Nuria Vilaboa, Richard Voellmy

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nuria VilaboaHospital Universitario La Paz-IdiPAZ, 28046 Madrid, Spain.ORCID 0000-0003-4473-4498
Richard VoellmyHSF Pharmaceuticals SA, 1814 La Tour-de-Peilz, Switzerland.ORCID 0000-0003-4183-0871
Hospital Universitario La Paz · ES

Funding

EPIDEMIOLOGY OF DRUG USE PATTERNS AMONG WOMENR29DA007406 · NIDA · GEORGIA STATE UNIVERSITY · PI STERK, CLAIRE E · 1992 to 1994
–
Comunidad de Madrid S2022/BMD-7406Foundation for Biomedical Research of the La Paz University Hospital-IdiPAZ "Luis Alvarez"Ministerio de Ciencia e Innovación PID2021-126325OB-I00
6 · The paper itself

Abstract

Withaferin A (WA) and celastrol (CEL) are major bioactive components of plants that have been widely employed in traditional medicine. The pleiotropic activities of plant preparations and the isolated compounds in vitro and in vivo have been documented in hundreds of studies. Both WA and CEL were shown to have anticancer activity. Although WA and CEL belong to different chemical classes, our synthesis of the available information suggests that the compounds share basic mechanisms of action. Both WA and CEL bind covalently to numerous proteins, causing the partial unfolding of some of these proteins and of many bystander proteins. The resulting proteotoxic stress, when excessive, leads to cell death. Both WA and CEL trigger the activation of the unfolded protein response (UPR) which, if the proteotoxic stress persists, results in apoptosis mediated by the PERK/eIF-2/ATF4/CHOP pathway or another UPR-dependent pathway. Other mechanisms of cell death may play contributory or even dominant roles depending on cell type. As shown in a proteomic study with WA, the compounds appear to function largely as electrophilic reactants, indiscriminately modifying reachable nucleophilic amino acid side chains of proteins. However, a remarkable degree of target specificity is imparted by the cellular context.

Indexed as

ProteomicsProteostasisWithanolidesPentacyclic TriterpenescelastrolPentacyclic Triterpeneswithaferin AWithanolidescelastrolIHSFprotein aggregationprotein unfoldingproteostasisWithaferin A

Identifiers

PMID38203539
PMCPMC10779417
OpenAlexW4390272959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.